Dalteparin
- Generic Name
- Dalteparin
- Brand Names
- Fragmin
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- S79O08V79F
- Background
Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more pre...
- Indication
Dalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk f...
- Associated Conditions
- Cardiovascular Events, Clotting, Deep Vein Thrombosis, Symptomatic Venous Thromboembolism, Venous Thromboembolism
- Associated Therapies
- -
Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Johns Hopkins All Children's Hospital
- Target Recruit Count
- 802
- Registration Number
- NCT06628778
- Locations
- πΊπΈ
Johns Hopkins All Children"s Hospital, Saint Petersburg, Florida, United States
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 6660
- Registration Number
- NCT05735639
- Locations
- π¬π§
Imperial College Hospital NHS Foundation Trust, London, United Kingdom
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
- Conditions
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- PharmaDiall Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05189002
- Locations
- π·πΊ
GBUZ of the city of Moscow City Clinical Hospital No. 1 named after NI Pirogova of the Moscow City Health Department, Moscow, Russian Federation
π·πΊSt. Petersburg GBUZ City Hospital of the Holy Martyr Elizabeth, St. Petersburg, Russian Federation
π·πΊFSBEI HE Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation, Nizhny Novgorod, Russian Federation
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Anthos Therapeutics, Inc.
- Target Recruit Count
- 1020
- Registration Number
- NCT05171075
- Locations
- π¨π³
Southern Medical University - Zhujiang Hospital, Guangdong, China
πΊπΈUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
πΊπΈWashington DC VAMC, Washington, District of Columbia, United States
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 80
- Registration Number
- NCT04850378
- Locations
- π©π°
Aarhus University Hospital, Aarhus, Denmark
PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 1100
- Registration Number
- NCT03559114
- Locations
- π¨π¦
Foothills Medical Centre, Calgary, Alberta, Canada
π¨π¦Royal Alexandra Hospital, Edmonton, Alberta, Canada
π¨π¦University of Alberta Hospital, Edmonton, Alberta, Canada
Venous Thromboprophylaxis in Bariatric Surgery
- Conditions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Target Recruit Count
- 118
- Registration Number
- NCT03218514
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 176
- Registration Number
- NCT03139487
- Locations
- π°π·
Asan Medical Center, Seoul, Korea, Republic of
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Fadoi Foundation, Italy
- Target Recruit Count
- 1168
- Registration Number
- NCT03045406
- Locations
- πΊπΈ
University of Southern California, Los Angeles, California, United States
πΊπΈJacksonville Center for Clinical Research, Jacksonville, Florida, United States
πΊπΈMayo Clinic Jacksonville, Jacksonville, Florida, United States
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 811
- Registration Number
- NCT02744092
- Locations
- πΊπΈ
Washington Hospital, Fremont, California, United States
πΊπΈMemorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
πΊπΈSaint Joseph's Medical Center, Stockton, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.